Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q1 2017 · 10-Q
Revenue$303.75M$303.75M+28.3% vs Q1 2016 Net Income-$16.29M-$16.29MN/M vs Q1 2016 EPS Diluted-$0.09-$0.09N/M vs Q1 2016 Operating Income-$20,208,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Free Cash Flowderived-$149,533,000N/M Margins · derivedOperating margin-6.7%+27.5 pt vs Q1 2016
Net margin-5.4%+29.7 pt vs Q1 2016
ended Mar 31, 2017 · filed May 4, 2017 · 34 d after period end